Furamag - instructions for use, dose, side effects, contraindications

active substance: potassium furozidine 50 mg; Excipients: magnesium hydroxycarbonate 50.00 mg, potassium carbonate 12.60 mg, talc 3.00 mg, composition of capsule number 3: titanium dioxide (E171) 1.3 2%, dye quinoline yellow (E104) 1.2%, gelatin 97.48 %.

Description:

hard gelatin capsules number 3 yellow. Contents of the capsules: powder from orange-brown to reddish-brown, particles of white, yellow, orange and orange-brown color are allowed.

Pharmacotherapeutic group:antimicrobial agent - nitrofuran

ATX: & nbsp

D.08.A.F Nitrofuran derivatives

J.01.X.E Nitrofuran derivatives

Pharmacodynamics:

A broad-spectrum antimicrobial agent belonging to the group of nitrofurans. Resistance to Furamago develops slowly and does not reach a high degree.

Effective against gram-positive cocci (Staphylococcus spp., Streptococcus spp.), Gram-negative rods (E. co, Salmonella spp., Shigella spp., Klebsiella spp., Enterobacter). Stable Plasmodium aeruginosa, Enterococcus spp., Acinetobacter spp., most strains Proteus spp., Serratia spp. The mechanism of action is related to the inhibition of the synthesis of nucleic acids. Depending on the concentration has a bactericidal or bacteriostatic effect. Towards Staphylococcus spp., E. coli, Aerobacter aerogenes, Bact. Citrovorum, Proteus mirabilis, Proteus morganii Furamag , in comparison with other nitrofurans, is more active. Furamag® shows a higher activity towards Enterococcus faecalis, Staphylococcus spp. compared with other groups of antimicrobial drugs.

Against most bacteria, the bacteriostatic concentration ranges from 1: 100,000 to 1: 200,000. The bactericidal concentration is approximately twice as large. Under the influence of nitrofurans in microorganisms, the respiratory chain and the cycle of tricarboxylic acids (Krebs cycle) are suppressed, as well as the inhibition of other biochemical processes of microorganisms, as a result of which their shell or cytoplasmic membrane is destroyed.As a result of the action of nitrofurans, microorganisms produce fewer toxins, so that an improvement in the general condition of the patient is possible even before the expressed suppression of microflora growth. Nitrofurans, unlike many other antimicrobial agents, not only do not inhibit the immune system of the body, but, on the contrary, activate it (increase the complement titre and the ability of leukocytes to phagocytose microorganisms). Nitrofurans in therapeutic doses stimulate leukopoiesis.

Pharmacokinetics:

Absorption occurs in the small intestine, by passive diffusion. Absorption of nitrofurans from the distal segment of the small intestine exceeds the absorption from the proximal and middle segments, respectively, 2 and 4 times (should be taken into account in the simultaneous treatment of urogenital infections and diseases, gastrointestinal tract, including chronic enteritis). Nitrofurans are poorly absorbed in the large intestine.

Furamag, being a mixture of potassium furosidine and magnesium hydroxycarbonate in the ratio 1: 1, with oral administration has a higher bioavailability than simple furazidine (after taking Furamag® capsule in an acidic stomach environment the conversion of potassium furozidine into poorly soluble furazidine).

In organism furazidine distributed evenly. Clinically important is the high content of the active substance in the lymph (delaying the spread of infection through the lymphatic ways). In bile, its concentration is several times higher than in serum, and in CSF it is several times lower than in serum. In saliva, the content of furazidine is 30% of its serum concentration. The concentration of furazidine in the blood and tissues is relatively small, which is due to its rapid release, while the concentration in the urine is much higher than in the blood. The maximum concentration in the blood is kept from 3 to 7 or 8 hours, in the urine furazidine is found 3-4 hours after application.

In contrast to nitrofurantoin (furadonin), after the adoption of Furamag®, the pH of urine does not change. Four hours after taking the drug Furamag®, the concentration of furazidine in the urine is significantly higher than the concentration that is formed after taking the same dose of the drug Furagin. Kidney secretion occurs by glomerular filtration and tubular secretion (85%), partially subjected to reverse reabsorption in tubules.At low concentrations of furazidine in the urine, the filtration and secretion process predominates, at high concentrations the secretion decreases and reabsorption increases. Furazidine, being a weak acid, does not dissociate in acidic urine, undergoes intensive reabsorption, which can increase the development of systemic side effects. With alkalization of urine, excretion of furazidine is enhanced. Furazidine slightly biotransformed (less than 10% of the administered dose), with a decrease in excretory function of the kidneys, the intensity of metabolism increases.

Indications:Infections caused by susceptible microorganisms to furazidinu: urogenital infections (acute cystitis, urethritis, pyelonephritis), skin and soft tissue infections, severe infected burns, gynecological infections. Prophylactically it is possible to apply at urological operations, a cystoscopy, a catheterization, etc.

Contraindications:

Hypersensitivity to nitrofuran group preparations, pregnancy and lactation period. Severe chronic renal failure. Children under 3 years (for this dosage form).

Carefully:

renal insufficiency, deficiency of glucose-6-phosphate dehydrogenase.

Dosing and Administration:

The drug is taken after meals, washed down with a lot of liquid.

Adults appoint 50-100 mg (1-2 capsules) 3 times a day. The course of treatment is 7-10 days. If necessary, after a 10-15 day break, repeat the course.

To prevent infection at urological operations, a cystoscopy, a catheterization, etc. the preparation appoint or nominate on 50 mg once for 30 minutes prior to procedure.

If you forget to take the next dose, take the next dose at the usual time. Do not take a double dose to replace the missed dose.

Side effects:

Furamag is low in toxicity. Rarely, side effects characteristic of other nitrofurans were observed: headache, dizziness, nausea, vomiting, loss of appetite, polyneuritis, violations of the liver, allergic reactions (skin rash, papular rashes).

If treatment of Furamag revealed side effects not listed in the instructions, then the physician should be informed.

Overdose:

In case of an overdose, symptoms of a neurotoxic nature, ataxia and tremor are observed.

In case of poisoning, drink plenty of fluids.For relief of acute symptoms, antihistamines are used. For the prevention of neuritis, the administration of vitamins (thiamine bromide) is possible.

Interaction:

Do not use Furamag along with ristomycin, chloramphenicol, sulfonamides (increases the risk of oppression of hematopoiesis).

During treatment it is advisable to refrain from drinking alcoholic beverages. may increase side effects.

It is not recommended simultaneously with nitrofurans to prescribe drugs that can "acidify" urine (including ascorbic acid, calcium chloride).

Special instructions:

To reduce the likelihood of side effects, Furamag is washed down with plenty of fluids. When side effects occur, the drug is discontinued (toxic effects are more frequent in patients with reduced renal excretory function).

Effect on the ability to drive transp. cf. and fur:Not checked

Form release / dosage:

Capsules 50 mg.

Packaging:10 capsules in a planar cell package. By 2,3,4 or 5 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use the drug after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:П N014425 / 01

Date of registration:18.03.2008

The owner of the registration certificate:Olainfarm, AOOlainfarm, AO Latvia

Manufacturer: & nbsp

Olainfarm, AO

Information update date: & nbsp11.11.2015

Illustrated instructions

Instructions

Furamag® (Furamag)